Vimarsana
Biggest News Aggregation in the World

Page 3 - Critically Ill News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Critically Ill. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Critically Ill Today - Breaking & Trending Today

Review into care of critically ill children a 'missed opportunity' - Vimarsana News

Review into care of critically ill children a 'missed opportunity'

Christians campaigning for greater transparency around decisions made in the care of critically ill children have expressed disappointment at the outcome of a review led by the Nuffield Council on Bioethics.

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults - Vimarsana News

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to...

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho - Vimarsana News

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S., it is estimated there are more than 40,000 cases of Acinetobacter each year and approximately 40...

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil - Vimarsana News

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

Advances CytoSorb as a Potentially Revolutionary Therapeutic Advance to Reverse Deadly Shock in Critically Ill and Cardiac Surgery PatientsPRINCETON, N.J., Aug. 31, 2023 -- CytoSorbents Corporation...

InflaRx: EMA Reviews MAA For Vilobelimab For Critically Ill COVID-19 Patients; Stock Up In Premarket - Vimarsana News

InflaRx: EMA Reviews MAA For Vilobelimab For Critically Ill COVID-19 Patients; Stock Up In Premarket

InflaRx N.V. (IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, Wednesday said the European Medicines Agency or EMA has validated its Marketing Authorization Application or MAA for Vilobelimab to treat Critically Ill COVID-19 Patients.